If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

13 Nov 2019 07:00

RNS Number : 1857T
Ideagen PLC
13 November 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

13 November 2019

Ideagen PLC

("Ideagen" "the Company" or "the Group")

Trading Update

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, today provides an update on trading for the six months ended 31 October 2019.

The Board is pleased to report that trading has remained strong in the first half of the financial year and that revenue and EBITDA are both expected to be significantly ahead of the same period last year and in line with management's expectations. This has been achieved through both organic revenue growth and the acquisitions of Redland Business Solutions Ltd (acquired in June 2019) and Optima Diagnostics Ltd (acquired in Oct 2019). The Company has a clear strategy to grow revenues organically and maintain high EBITDA margins whilst transitioning from a perpetual licence to a SaaS based subscription model. The successful execution of this strategy will provide an even more robust business model and a higher quality of earnings over the medium term without impacting on the short-term profitability of the business.

The Board considers that the key growth metric for the Group is based on Annual Recurring Revenue ("ARR"). ARR is the value of the Group's contracted recurring revenue book at any point in time, which will be recognised over the next 12 month period.

The Group's ARR has grown by approximately 20 per cent. from £36.4 million on 30 April 2019 to £43.9 million on 31 October 2019. This comprises of acquisition-led growth of £3.8 million combined with organic growth of £3.7 million within the period, representing approximately a 20 per cent. organic growth rate on an annualised basis. Group performance is based on strong customer demand and sales execution in the period and indicates that the transition to a recurring model is progressing successfully and is ahead of schedule.

Total organic revenue growth in the period was 7 per cent. which, in the context of an accelerated SaaS transition, represents a strong performance. Recognised Recurring revenue is expected to be approximately 74 per cent. of total revenue and is expected to rise to over 80 per cent. in the next full financial year.

The Company continues to compete and win new business within the UK and international markets reflecting the Company's global expansion. During the period, the Company won over 240 new customer logos including Emirates Airline, Emirates Catering, Alexander Hall, Mallinckrodt Pharmaceuticals, Freightliner, Vietjet Air, Mylan Pharmaceuticals and Royal London.

At the period end the group had net debt of £18.2 million (30 April 2019: net debt of £1.3 million) after spending £19.8 million on acquisitions. Operating cash generation in the period remained robust and in line with the Board's expectations. 

Ben Dorks, Chief Executive Officer of Ideagen, commented:

"I am pleased to report an excellent start to Ideagen's financial year. Our core markets are strong and underpin the demand we have seen this half. We continue to execute our strategy, delivering growth and investing in the business whilst tightly managing the cost base. The Company has continued to make acquisitions which have further enhanced our global reach, customer base and product capability.

Cash generation has been good which coupled with further growth in new SaaS recurring revenues and an increase in repeat business from our growing customer base provides a strong platform for the second half.

The market opportunity remains large and long term and given the Group's position as a leader in the Governance, Risk and Compliance market, the Board is optimistic about the Group's continued growth prospects."

 Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

Ben Dorks, Chief Executive Officer

Graeme Spenceley, Chief Financial Officer

 finnCap Limited

020 7220 0500

Henrik Persson/James Thompson (Nomad)

Alice Lane (ECM)

 

Canaccord Genuity Limited

 020 7523 8000

Simon Bridges

Richard Andrews

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides IRM software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTVLLFFKFFZFBE
Date   Source Headline
14th Oct 20215:46 pmRNSIssue of new shares under the SIP
14th Oct 20217:00 amRNSSale of Pentana Compliance
11th Oct 20212:25 pmRNSNotice of AGM
1st Oct 20213:15 pmRNSTotal Voting Rights
1st Oct 20217:00 amRNSChange of Auditor
24th Sep 20219:37 amRNSIssue of Shares, PDMR Dealing & TVR
13th Sep 20214:50 pmRNSExercise of Options and Total Voting Rights
10th Sep 20216:05 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSTotal Voting Rights
31st Aug 20219:32 amRNSHolding(s) in Company
26th Aug 20217:00 amRNSPDMR Dealing and Total Voting Rights
11th Aug 20212:02 pmRNSIssue of new shares under the SIP and TVR
11th Aug 20217:00 amRNSExercise of Options and Total Voting Rights
23rd Jul 20214:54 pmRNSPDMR Dealing and Total Voting Rights
22nd Jul 20217:00 amRNSFinal Results
20th Jul 20212:03 pmRNSIssue of new shares under the SIP
19th Jul 20217:00 amRNSTwo highly complementary strategic acquisitions
15th Jul 20214:17 pmRNSExercise of share options and Total Voting Rights
16th Jun 20217:00 amRNSIssue of new shares under the SIP
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:36 pmRNSPrice Monitoring Extension
21st May 20217:00 amRNSDirector/PDMR Shareholding
13th May 20217:00 amRNSPre-Close Trading Update and Board Change
28th Apr 20217:00 amRNSDirector Dealings and Total Voting Rights
14th Apr 202112:40 pmRNSIssue of Shares, PDMR Dealing & TVR
16th Mar 20213:33 pmRNSIssue of new shares under the SIP and TVR
9th Mar 20217:00 amRNSAcquisition of Qualtrax
26th Feb 20211:49 pmRNSHolding(s) in Company
25th Feb 20214:00 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSHolding(s) in Company
23rd Feb 20217:00 amRNSPDMR Dealing and Total Voting Rights
16th Feb 20215:15 pmRNSIssue of Equity & Total Voting Rights
12th Feb 20217:00 amRNSDirector/PDMR Dealings
3rd Feb 20219:35 amRNSExtension to 2018 LTIP Awards
26th Jan 20217:00 amRNSSuccession of Chairman
26th Jan 20217:00 amRNSUnaudited Interim Results
25th Jan 20214:26 pmRNSH1 Results Presentation
22nd Jan 20217:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
30th Dec 20207:21 amRNSCompletion of Huddle Acquisition
23rd Dec 202011:30 amRNSAcquisition of Huddle
22nd Dec 20202:04 pmRNSHolding(s) in Company
18th Dec 202012:56 pmRNSIssue of Shares & Director/PDMR Shareholding
9th Dec 20207:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20204:53 pmRNSPrimaryBid.com Offer
8th Dec 20204:50 pmRNSProposed Fundraise of £48.7 million
20th Nov 20203:40 pmRNSIssue of Equity, PDMR Dealing and TVR
17th Nov 202012:05 pmRNSChange of Registered Office
13th Nov 20203:51 pmRNSPDMR Shareholding and Exercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.